Instructions for Use
For Use with GeneXpert Dx System or GeneXpert Infinity System

REF XPRSARS-COV2-10
Trademark, Patents, and Copyright Statements

Cepheid®, the Cepheid logo, GeneXpert®, and Xpert® are trademarks of Cepheid, registered in the U.S. and other countries. All other trademarks are the property of their respective owners.

THE PURCHASE OF THIS PRODUCT CONVEYS TO THE BUYER THE NON-TRANSFERABLE RIGHT TO USE IT IN ACCORDANCE WITH THESE INSTRUCTIONS FOR USE. NO OTHER RIGHTS ARE CONVEYED EXPRESSLY, BY IMPLICATION OR BY ESTOPPEL. FURTHERMORE, NO RIGHTS FOR RESALE ARE CONFERRED WITH THE PURCHASE OF THIS PRODUCT.

© 2020–2022 Cepheid.

See Section 26, Revision History for a description of changes.
Xpert® Xpress SARS-CoV-2

For use under Emergency Use Authorization (EUA) only.

1 Proprietary Name
Xpert® Xpress SARS-CoV-2

2 Common or Usual Name
Xpert Xpress SARS-CoV-2

3 Intended Use
The Xpert Xpress SARS-CoV-2 is a rapid, real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens (i.e., nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab or nasal wash/aspirate) collected from individuals suspected of COVID-19 by their healthcare provider.

Testing of nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab or nasal wash/aspirate specimens using the Xpert Xpress SARS-CoV-2 test run on the GeneXpert Dx and GeneXpert Infinity systems is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet requirements to perform high or moderate complexity tests.

Testing of nasopharyngeal, nasal, or mid-turbinate swab specimens using the Xpert Xpress SARS-CoV-2 test run on the GeneXpert Xpress System (Tablet and Hub Configurations) is limited to laboratories certified under CLIA that meet requirements to perform high, moderate, or waived complexity tests. Testing of these specimens is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Results are for the detection of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of active infection with SARS-CoV-2; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Testing with the Xpert Xpress SARS-CoV-2 test is intended for use by trained operators who are proficient in performing tests using either GeneXpert Dx, GeneXpert Infinity and/or GeneXpert Xpress systems. The Xpert Xpress SARS-CoV-2 test is only for use under the Food and Drug Administration’s Emergency Use Authorization.

4 Summary and Explanation
An outbreak of respiratory illness of unknown etiology in Wuhan City, Hubei Province, China was initially reported to the World Health Organization (WHO) on December 31, 2019.¹ Chinese authorities identified a novel coronavirus (2019-nCoV), which has resulted in thousands of confirmed human infections in multiple provinces throughout China and exported cases in several Southeast Asian countries and more recently the United States. Cases of severe illness and some deaths have been reported. The International Committee for Taxonomy of Viruses (ICTV) renamed the virus SARS-CoV-2.²
The Xpert Xpress SARS-CoV-2 test is a molecular in vitro diagnostic test that aids in the detection and diagnosis SARS-CoV-2 and is based on widely used nucleic acid amplification technology. The Xpert Xpress SARS-CoV-2 test contains primers and probes and internal controls used in RT-PCR for the in vitro qualitative detection of SARS-CoV-2 RNA in upper respiratory specimens.

5 Principle of the Procedure

The Xpert Xpress SARS-CoV-2 test is an automated in vitro diagnostic test for qualitative detection of nucleic acid from SARS-CoV-2. The Xpert Xpress SARS-CoV-2 test is performed on GeneXpert Instrument Systems.

The GeneXpert Instrument Systems automate and integrate sample preparation, nucleic acid extraction and amplification, and detection of the target sequences in simple or complex samples using real-time PCR assays. The systems consist of an instrument, computer, and preloaded software for running tests and viewing the results. The systems require the use of single-use disposable cartridges that hold the RT-PCR reagents and host the RT-PCR process. Because the cartridges are self-contained, cross-contamination between samples is minimized. For a full description of the systems, see the GeneXpert Dx System Operator Manual or the GeneXpert Infinity System Operator Manual.

The Xpert Xpress SARS-CoV-2 test includes reagents for the detection of RNA from SARS-CoV-2 in nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab and/or nasal wash/aspirate specimens. A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included in the cartridge utilized by the GeneXpert instrument. The SPC is present to control for adequate processing of the sample and to monitor for the presence of potential inhibitor(s) in the RT-PCR reaction. The SPC also ensures that the RT-PCR reaction conditions (temperature and time) are appropriate for the amplification reaction and that the RT-PCR reagents are functional. The PCC verifies reagent rehydration, PCR tube filling, and confirms that all reaction components are present in the cartridge including monitoring for probe integrity and dye stability.

The nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab specimen and/or nasal wash/aspirate specimen is collected and placed into a viral transport tube containing 3 mL transport medium or 3 mL of saline. The specimen is briefly mixed by rapidly inverting the collection tube 5 times. Using the supplied transfer pipette, the sample is transferred to the sample chamber of the Xpert Xpress SARS-CoV-2 cartridge. The GeneXpert cartridge is loaded onto the GeneXpert Instrument System platform, which performs hands-off, automated sample processing, and real-time RT-PCR for detection of viral RNA.

6 Materials Provided

The Xpert Xpress SARS-CoV-2 kit contains sufficient reagents to process 10 specimens or quality control samples. The kit contains the following:

**Xpert Xpress SARS-CoV-2 Cartridges with Integrated Reaction Tubes**

- Bead 1, Bead 2, and Bead 3 (freeze-dried) 1 of each per cartridge
- Lysis Reagent 1.5 mL per cartridge
- Binding Reagent 1.5 mL per cartridge
- Elution Reagent 3.0 mL per cartridge
- Disposable Transfer Pipettes 10-12 per kit
- CD 1 per kit
- Assay Definition File (ADF)
- Instructions to import ADF into the software
- Flyer 1 per kit
- Directions to locate the product insert on www.cepheid.com.

**Note**

Safety Data Sheets (SDS) are available at www.cepheid.com or www.cepheidinternational.com under the SUPPORT tab.
The bovine serum albumin (BSA) in the beads within this product was produced and manufactured exclusively from bovine plasma sourced in the United States. No ruminant protein or other animal protein was fed to the animals; the animals passed ante- and post-mortem testing. During processing, there was no mixing of the material with other animal materials.

7 Storage and Handling

- Store the Xpert Xpress SARS-CoV-2 cartridges at 2-28 °C.
- Do not open a cartridge lid until you are ready to perform testing.
- Do not use a cartridge that is wet or has leaked.

8 Materials Required but Not Provided

GeneXpert Dx or GeneXpert Infinity systems (catalog number varies by configuration): GeneXpert instrument, computer, barcode scanner, operator manual.

- For GeneXpert Dx System: GeneXpert Dx software version 4.7b or higher
- For GeneXpert Infinity-80 and Infinity-48s systems: Xpertise software version 6.4b or higher

9 Materials Available but Not Provided

SeraCare AccuPlex™ Reference Material Kit, catalog number 0505-0126 (Order Code CEPHEID)

10 Warnings and Precautions

10.1 General

- For in vitro diagnostic use.
- For emergency use only.
- This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories.
- This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other virus or pathogens.
- This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
- Positive results are indicative of presence of SARS-CoV-2-RNA.
- Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.
- Performance characteristics of this test have only been established with nasopharyngeal swab specimens. The performance of this assay with other specimen types or samples has not been evaluated.
- Treat all biological specimens, including used cartridges, as if capable of transmitting infectious agents. Because it is often impossible to know which might be infectious, all biological specimens should be handled using standard precautions. Guidelines for specimen handling are available from the U.S. Centers for Disease Control and Prevention and the Clinical and Laboratory Standards Institute.
- Follow safety procedures set by your institution for working with chemicals and handling biological specimens.
- Consult your institution’s environmental waste personnel on proper disposal of used cartridges, which may contain amplified material. This material may exhibit characteristics of federal EPA Resource Conservation and Recovery Act (RCRA) hazardous waste requiring specific disposal requirements. Check state and local regulations as they may differ from federal disposal regulations. Institutions should check the hazardous waste disposal requirements within their respective countries.
10.2 Specimens

- Maintain proper storage conditions during specimen transport to ensure the integrity of the specimen (see Specimen Collection, Transport, and Storage). Specimen stability under shipping conditions other than those recommended has not been evaluated.

10.3 Assay/Reagent

- Do not open the Xpert Xpress SARS-CoV-2 cartridge lid except when adding specimen.
- Do not use a cartridge that has been dropped after removing it from the packaging.
- Do not shake the cartridge. Shaking or dropping the cartridge after opening the cartridge lid may yield non-determinate results.
- Do not place the Sample ID label on the cartridge lid or on the barcode label on the cartridge.
- Do not use a cartridge with a damaged barcode label.
- Do not use a cartridge that has a damaged reaction tube.
- Each single-use Xpert Xpress SARS-CoV-2 cartridge is used to process one test. Do not reuse processed cartridges.
- Each single-use disposable pipette is used to transfer one specimen. Do not reuse disposable pipettes.
- Do not use a cartridge if it appears wet or if the lid seal appears to have been broken.
- Wear clean lab coats and gloves. Change gloves between the handling of each specimen.
- In the event of a spill of specimens or controls, wear gloves and absorb the spill with paper towels. Then, thoroughly clean the contaminated area with a 10% freshly prepared household chlorine bleach. Allow a minimum of two minutes of contact time. Ensure the work area is dry before using 70% denatured ethanol to remove bleach residue. Allow surface to dry completely before proceeding. Or, follow your institution’s standard procedures for a contamination or spill event. For equipment, follow the manufacturer’s recommendations for decontamination of equipment.
- Biological specimens, transfer devices, and used cartridges should be considered capable of transmitting infectious agents requiring standard precautions. Follow your institution’s environmental waste procedures for proper disposal of used cartridges and unused reagents. These materials may exhibit characteristics of chemical hazardous waste requiring specific disposal. If country or regional regulations do not provide clear direction on proper disposal, biological specimens and used cartridges should be disposed per WHO [World Health Organization] medical waste handling and disposal guidelines.

11 Chemical Hazards\(^5,6\)

Signal Word: WARNING

UN GHS Hazard Statements

- Harmful if swallowed.
- May be harmful in contact with skin.
- Causes eye irritation.

UN GHS Precautionary Statements

Prevention

- Wash hands thoroughly after handling.

Response

- Call a POISON CENTER or doctor/physician if you feel unwell.
- If skin irritation occurs: Get medical advice/attention.
- IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- If eye irritation persists: Get medical advice/attention.
12 Specimen Collection, Transport, and Storage

Proper specimen collection, storage, and transport are critical to the performance of this test. Inadequate specimen collection, improper specimen handling and/or transport may yield a false result. See Section 12.1. Nasopharyngeal Swab Collection Procedure, Section 12.2. Oropharyngeal Swab Collection Procedure, Section 12.3. Nasal Swab Collection Procedure, Section 12.4. Mid-Turbinate Swab Collection Procedure, and Section 12.5. Nasal Wash/Aspirate Procedure.

Nasopharyngeal, nasal, and mid-turbinate swabs and nasal wash/aspirate specimens can be stored at room temperature (15–30 °C) for up to 8 hours and refrigerated (2–8 °C) up to seven days until testing is performed on the GeneXpert Instrument Systems. For oropharyngeal swab specimen transport and storage requirements and additional information, refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19) using the link provided below.


12.1 Nasopharyngeal Swab Collection Procedure

1. Insert the swab into either nostril, passing it into the posterior nasopharynx (see Figure 1).

2. Rotate swab by firmly brushing against the nasopharynx several times. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3 mL of saline.

3. Break swab at the indicated break line and cap the specimen collection tube tightly.

12.2 Oropharyngeal Swab Collection Procedure

1. Swab the posterior pharynx, tonsils, and other inflamed areas. Avoid touching the tongue, cheeks, and teeth with the swab when collecting specimens.

2. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3 mL of saline. Break swab at the indicated break line and cap the specimen collection tube tightly.

12.3 Nasal Swab Collection Procedure

1. Insert a nasal swab 1 to 1.5 cm into a nostril. Rotate the swab against the inside of the nostril for 3 seconds while applying pressure with a finger to the outside of the nostril (see Figure 2).
Figure 2. Nasal Swab Collection for First Nostril

2. Repeat on the other nostril with the same swab, using external pressure on the outside of the other nostril (see Figure 3). To avoid specimen contamination, do not touch the swab tip to anything other than the inside of the nostril.

Figure 3. Nasal Swab Collection for Second Nostril

3. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3 mL of saline. Break swab at the indicated break line and cap the specimen collection tube tightly.

12.4 Mid-Turbinate Swab Collection Procedure

1. Insert the mid-turbinate swab into either nostril, passing it into the mid-turbinate area (see Figure 4).
2. Rotate swab by firmly brushing against the mid-turbinate area several times.
3. Remove and place the swab into the tube containing 3 mL of viral transport medium or 3 mL of saline.
4. Break swab at the indicated break line and cap the specimen collection tube tightly.

12.5 Nasal Wash/Aspirate Procedure
Using a clean transfer pipette, transfer 600 µL of the sample into the tube containing 3 mL of viral transport medium or 3 mL of saline and then cap the tube.

13 Procedure

13.1 Preparing the Cartridge

Start the test within 30 minutes of adding the sample to the cartridge.

1. Remove a cartridge from the package.
2. Check the specimen transport tube is closed.
3. Mix specimen by rapidly inverting the specimen transport tube 5 times. Open the cap on the specimen transport tube.
4. Open the cartridge lid.
5. Remove the transfer pipette from the wrapper.
6. Squeeze the top bulb of the transfer pipette completely and then place the pipette tip in the specimen transport tube (see Figure 4).
7. Release the top bulb of the pipette to fill the pipette before removing from the tube. After filling pipette, excess sample will be seen in the overflow reservoir bulb of the pipette (see Figure 4). Check that the pipette does not contain bubbles.

8. To transfer the sample to the cartridge, squeeze the top bulb of the transfer pipette completely again to empty the contents of the pipette (300 µL) into the large opening (Sample Chamber) in the cartridge shown in Figure 5. Dispose of the used pipette.

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Squeeze here</td>
</tr>
<tr>
<td>2</td>
<td>Pipette</td>
</tr>
<tr>
<td>3</td>
<td>Overflow reservoir bulb</td>
</tr>
<tr>
<td>4</td>
<td>Sample</td>
</tr>
</tbody>
</table>

9. Close the cartridge lid.

13.2 External Controls

External controls described in Section 9 are available but not provided and may be used in accordance with local, state, and federal accrediting organizations, as applicable.
To run a control using the Xpert Xpress SARS-CoV-2 test, perform the following steps:

1. Mix control by rapidly inverting the external control tube 5 times. Open cap on external control tube.
2. Open the cartridge lid.
3. Using a clean transfer pipette, transfer one draw of the external control sample (300 µL) into the large opening (Sample Chamber) in the cartridge shown in Figure 6.

### 14 Running the Test

- For the GeneXpert Dx System, see Section 14.1.
- For the GeneXpert Infinity System, see Section 14.2.

#### 14.1 GeneXpert Dx System

#### 14.1.1 Starting the Test

**Important**

Before you start the test, make sure that:

- The system is running the correct GeneXpert Dx software version shown in section - Materials Required but Not Provided.
- The correct assay definition file is imported into the software.

This section lists the basic steps for running the test. For detailed instructions, see the GeneXpert Dx System Operator Manual.

**Note**

The steps you follow can be different if the system administrator changed the default workflow of the system.

1. Turn on the GeneXpert Dx System, then turn on the computer and log on. The GeneXpert software will launch automatically. If it does not, double-click the GeneXpert Dx software shortcut icon on the Windows® desktop.
2. Log on using your username and password.
3. In the GeneXpert System window, click Create Test. The Create Test window displays. The Scan Patient ID barcode dialog box displays.
4. Scan or type in the Patient ID. If typing the Patient ID, make sure the Patient ID is typed correctly. The Patient ID is associated with the test results and displays in the View Results window and all the reports. The Scan Sample ID barcode dialog box displays.
5. Scan or type in the Sample ID. If typing the Sample ID, make sure the Sample ID is typed correctly. The Sample ID is associated with the test results and displays in the View Results window and all the reports. The Scan Cartridge Barcode dialog box displays.
6. Scan the barcode on the cartridge. Using the barcode information, the software automatically fills the boxes for the following fields: Select Assay, Reagent Lot ID, Cartridge SN, and Expiration Date.

If the barcode on the cartridge does not scan, then repeat the test with a new cartridge. If you have scanned the cartridge barcode in the software and the assay definition file is not available, a screen displays indicating the assay definition file is not loaded on the system. If this screen displays, contact Cepheid Technical Support.

7. Click Start Test. In the dialog box that displays, type your password, if required.
8. Open the instrument module door with the blinking green light and load the cartridge.
9. Close the door. The test starts and the green light stops blinking. When the test is finished, the light turns off.
10. Wait until the system releases the door lock before opening the module door, then remove the cartridge.
11. Dispose of the used cartridges in the appropriate specimen waste containers according to your institution's standard practices.
14.1.2 Viewing and Printing Results

This section lists the basic steps for viewing and printing results. For more detailed instructions on how to view and print the results, see the GeneXpert Dx System Operator Manual.

1. Click the View Results icon to view results.

2. Upon completion of the test, click the Report button of the View Results window to view and/or generate a PDF report file.

14.2 GeneXpert Infinity System

14.2.1 Starting the Test

Before you start the test, make sure that:

**Important**
- The system is running the correct Xpertise software version shown in section - Materials Required but Not Provided.
- The correct assay definition file is imported into the software.

This section lists the basic steps for running the test. For detailed instructions, see the GeneXpert Infinity System Operator Manual.

**Note** The steps you follow can be different if the system administrator changed the default workflow of the system.

1. Power up the instrument. The Xpertise software will launch automatically. If it does not, double-click the Xpertise software shortcut icon on the Windows desktop.

2. Log on to the computer, then log on to the GeneXpert Xpertise software using your user name and password.

3. In the Xpertise Software Home workspace, click Orders and in the Orders workspace, click Order Test. The Order Test - Patient ID workspace displays.

4. Scan or type in the Patient ID. If typing the Patient ID, make sure the Patient ID is typed correctly. The Patient ID is associated with the test results and displays in the View Results window and all the reports.

5. Enter any additional information required by your institution, and click the CONTINUE button. The Order Test - Sample ID workspace displays.

6. Scan or type in the Sample ID. If typing the Sample ID, make sure the Sample ID is typed correctly. The Sample ID is associated with the test results and displays in the View Results window and all the reports.

7. Click the CONTINUE button. The Order Test - Assay workspace displays.

8. Scan the barcode on the cartridge. Using the barcode information, the software automatically fills the boxes for the following fields: Select Assay, Reagent Lot ID, Cartridge SN, and Expiration Date.

**Note** If the barcode on the cartridge does not scan, then repeat the test with a new cartridge. If you have scanned the cartridge barcode in the software and the assay definition file is not available, a screen displays indicating the assay definition file is not loaded on the system. If this screen displays, contact Cepheid Technical Support.

After the cartridge is scanned, the Order Test - Test Information workspace displays.

9. Verify that the information is correct, and click Submit. In the dialog box that displays, type your password, if required.

10. Place the cartridge on the conveyor belt. The cartridge automatically loads, the test runs, and the used cartridge are placed into the waste container.

14.2.2 Viewing and Printing Results

This section lists the basic steps for viewing and printing results. For more detailed instructions on how to view and print the results, see the GeneXpert Infinity System Operator Manual.

1. In the Xpertise Software Home workspace, click the RESULTS icon. The Results menu displays.

2. In the Results menu, select the VIEW RESULTS button. The View Results workspace displays showing the test results.

3. Click the REPORT button to view and/or generate a PDF report file.
15 Quality Control

15.1 Internal Controls
Each cartridge includes a Sample Processing Control (SPC) and Probe Check Control (PCC).

Sample Processing Control (SPC) – Ensures that the sample was processed correctly. The SPC verifies that sample processing is adequate. Additionally, this control detects sample-associated inhibition of the real-time PCR assay, ensures that the PCR reaction conditions (temperature and time) are appropriate for the amplification reaction, and that the PCR reagents are functional. The SPC should be positive in a negative sample and can be negative or positive in a positive sample. The SPC passes if it meets the validated acceptance criteria.

Probe Check Control (PCC) – Before the start of the PCR reaction, the GeneXpert system measures the fluorescence signal from the probes to monitor bead rehydration, reaction tube filling, probe integrity, and dye stability. The PCC passes if it meets the validated acceptance criteria.

15.2 External Controls
External controls should be used in accordance with local, state, and federal accrediting organizations as applicable.

16 Interpretation of Results
The results are interpreted automatically by the GeneXpert System and are clearly shown in the View Results window. The Xpert Xpress SARS-CoV-2 test provides test results based on the detection of two gene targets according to the algorithms shown in Table 1.
Table 1. Xpert Xpress SARS-CoV-2 Possible Results

<table>
<thead>
<tr>
<th>Result Text</th>
<th>N2</th>
<th>E</th>
<th>SPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 POSITIVE</td>
<td>+</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>SARS-CoV-2 PRESUMPTIVE POS</td>
<td>-</td>
<td>+</td>
<td>+/-</td>
</tr>
<tr>
<td>SARS-CoV-2 NEGATIVE</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>INVALID</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

See Table 2 to interpret test result statements for the Xpert Xpress SARS-CoV-2 test.

Table 2. Xpert Xpress SARS-CoV-2 Results and Interpretation

<table>
<thead>
<tr>
<th>Result</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 POSITIVE</td>
<td>The 2019 novel coronavirus (SARS-CoV-2) target nucleic acids are detected.</td>
</tr>
<tr>
<td></td>
<td>• The SARS-CoV-2 signal for the N2 nucleic acid target or signals for both nucleic acid targets (N2 and E) have a Ct within the valid range and endpoint above the minimum setting.</td>
</tr>
<tr>
<td></td>
<td>• SPC: NA; SPC is ignored because coronavirus target amplification occurred.</td>
</tr>
<tr>
<td></td>
<td>• Probe Check: PASS; all probe check results pass.</td>
</tr>
<tr>
<td>SARS-CoV-2 PRESUMPTIVE POS</td>
<td>The 2019 novel coronavirus (SARS-CoV-2) nucleic acids may be present. Sample should be retested according to the Retest Procedure in Section 17.2. For samples with a repeated presumptive positive result, additional confirmatory testing may be conducted, if it is necessary to differentiate between SARS-CoV-2 and SARS-CoV-1 or other Sarbecovirus currently unknown to infect humans, for epidemiological purposes or clinical management.</td>
</tr>
<tr>
<td></td>
<td>• The SARS-CoV-2 signal for only the E nucleic acid target has a Ct within the valid range and endpoint above the minimum setting.</td>
</tr>
<tr>
<td></td>
<td>• SPC: NA; SPC is ignored because a target amplification has occurred.</td>
</tr>
<tr>
<td></td>
<td>• Probe Check: PASS; all probe check results pass.</td>
</tr>
<tr>
<td>SARS-CoV-2 NEGATIVE</td>
<td>The 2019 novel coronavirus (SARS-CoV-2) target nucleic acids are not detected.</td>
</tr>
<tr>
<td></td>
<td>• The SARS-CoV-2 signals for two nucleic acid targets (N2 and E) do not have a Ct within the valid range and endpoint above the minimum setting.</td>
</tr>
<tr>
<td></td>
<td>• SPC: PASS; SPC has a Ct within the valid range and endpoint above the minimum setting.</td>
</tr>
<tr>
<td></td>
<td>• Probe Check: PASS. All probe check results pass.</td>
</tr>
<tr>
<td>INVALID</td>
<td>SPC does not meet acceptance criteria. Presence or absence of the 2019 novel coronavirus (SARS-CoV-2) nucleic acids cannot be determined. Repeat test according to the Retest Procedure (Section 17.2).</td>
</tr>
<tr>
<td></td>
<td>• SPC: FAIL; SPC and SARS-CoV-2 signals do not have a Ct within valid range and endpoint below minimum setting.</td>
</tr>
<tr>
<td></td>
<td>• Probe Check: PASS. All probe check results pass.</td>
</tr>
</tbody>
</table>
**Xpert® Xpress SARS-CoV-2**

### Result Interpretation

<table>
<thead>
<tr>
<th>Result</th>
<th>Interpretation</th>
</tr>
</thead>
</table>
| ERROR          | Presence or absence of the 2019 novel coronavirus (SARS-CoV-2) nucleic acids cannot be determined. Repeat test according to the Retest Procedure (Section 17.2).<br>  
  - SARS-CoV-2: NO RESULT<br>  - SPC: NO RESULT<br>  - Probe Check: FAIL; all or one of the probe check results fail.\(^1\)  
  \(^1\)If the probe check passes, the error is caused by the maximum pressure limit exceeding the acceptable range, no sample added, or by a system component failure. |
| NO RESULT      | Presence or absence of the 2019 novel coronavirus (SARS-CoV-2) nucleic acids cannot be determined. Repeat test according to the Retest Procedure (Section 17.2). A NO RESULT indicates that insufficient data were collected. For example, the operator stopped a test that was in progress.<br>  
  - SARS-CoV-2: NO RESULT<br>  - SPC: NO RESULT<br>  - Probe Check: NA (not applicable) |

The Xpert Xpress SARS-CoV-2 test includes an Early Assay Termination (EAT) function, which will provide earlier time to results in high titer specimens if the signal from the target nucleic acid reaches a predetermined threshold before the full 45 PCR cycles have been completed. When SARS-CoV-2 titers are high enough to initiate the EAT function, the SPC amplification curve may not be seen and its results may not be reported.

### 17 Retests

#### 17.1 Reasons to Repeat the Assay

If any of the test results mentioned below occur, repeat the test once according to instructions in Section 17.2, Retest Procedure.

- A **PRESUMPTIVE POS** result indicates the 2019 novel coronavirus (SARS-CoV-2) nucleic acids may be present. Only one of the SARS-CoV-2 nucleic acid target was detected (E gene) while the other SARS-CoV-2 nucleic acid target (N2 gene) was not detected.
- An **INVALID** result indicates that the control SPC failed. The sample was not properly processed, PCR is inhibited, or the sample was not properly collected.
- An **ERROR** result could be due to, but not limited to, Probe Check Control failure, system component failure, no sample added, or the maximum pressure limits were exceeded.
- A **NO RESULT** indicates that insufficient data were collected. For example, cartridge failed integrity test, the operator stopped a test that was in progress, or a power failure occurred.

If an External Control fails to perform as expected, repeat external control test and/or contact Cepheid for assistance.

#### 17.2 Retest Procedure

To retest a non-determinate result (**INVALID, NO RESULT, or ERROR**), or a **PRESUMPTIVE POS** result, use a new cartridge.

Use the leftover sample from the original specimen transport medium tube or new external control tube.

2. Check the specimen transport tube or external control tube is closed.
3. Mix the sample by rapidly invert the specimen transport medium tube or external control tube 5 times. Open the cap on the specimen transport tube or external control tube.
4. Open the cartridge lid.
5. Using a clean transfer pipette (supplied), transfer sample (one draw) to the sample chamber with the large opening in the cartridge.
6. Close the cartridge lid.

18 Limitations

- The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.
- Performance of the Xpert Xpress SARS-CoV-2 test has only been established in nasopharyngeal swab specimens. Use of the Xpert Xpress SARS-CoV-2 test with other specimen types has not been assessed and performance characteristics are unknown.
- Oropharyngeal, nasal swabs and mid-turbinate swabs (self-collected under supervision of or collected by a healthcare provider) as well as nasal wash/aspirate are considered acceptable specimen types for use with the Xpert Xpress SARS-CoV-2 test but performance with these specimen types has not been established.
- A false negative result may occur if a specimen is improperly collected, transported or handled. False negative results may also occur if inadequate numbers of organisms are present in the specimen.
- As with any molecular test, mutations within the target regions of Xpert Xpress SARS-CoV-2 could affect primer and/or probe binding resulting in failure to detect the presence of virus.
- This test cannot rule out diseases caused by other bacterial or viral pathogens.
- The performance of this device has not been assessed in a population vaccinated against COVID-19.

19 Conditions of Authorization for Laboratories


However, to assist clinical laboratories and/or Point of Care Settings using the Xpert Xpress SARS-CoV-2 (referred to in the Letter of Authorization as “Your Product”), the relevant Conditions of Authorization are listed below.

- Authorized laboratories using your product must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using your product must use your product as outlined in the authorized labeling. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- Authorized laboratories that receive your product must notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- Authorized laboratories using your product must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- Authorized laboratories using your product must collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA Reporting@fda.hhs.gov) and Cepheid (+1 888 838 3222 or techsupport@cepheid.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the test of which they become aware.
- All operators using your product must be appropriately trained in performing and interpreting the results of your product, use appropriate personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.
- You, authorized distributors, and authorized laboratories using your product must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

The letter of authorization refers to “authorized laboratories” as follows: “Testing of nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab or nasal wash/aspirate specimens using the Xpert Xpress SARS-CoV-2 test run on the GeneXpert Dx and GeneXpert Infinity Systems is limited to laboratories certified under the Clinical Laboratory
Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high or moderate complexity tests. Testing of nasopharyngeal, nasal, or mid-turbinate swab specimens using the Xpert Xpress SARS-CoV-2 test run on the GeneXpert Xpress System (Tablet and Hub Configurations) is limited to laboratories certified under CLIA that meet requirements to perform high, moderate, or waived complexity tests. Testing of these specimens is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.”

20 Performance Characteristics

20.1 Clinical Evaluation

The performance of the Xpert Xpress SARS-CoV-2 test was evaluated using archived clinical nasopharyngeal (NP) swab specimens in viral transport medium. A total of 45 SARS-CoV-2 positive and 45 SARS-CoV-2 negative NP swab specimens were tested with Xpert Xpress SARS-CoV-2 in a randomized and blinded fashion.

All the 45 SARS-CoV-2 positive specimens and 30 of the 45 SARS-CoV-2 negative specimens were collected during COVID-19 pandemic in the US and had previously been characterized as positive or negative for SARS-CoV-2 by an EUA RT-PCR test. Fifteen of the 45 SARS-CoV-2 negative NP swab specimens were collected before December 2019 and are expected to be negative for SARS-CoV-2.

Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) were determined by comparing the results of the Xpert Xpress SARS-CoV-2 test relative to the expected results. Results of these 90 archived clinical NP swab specimens are shown in Table 3. The PPA was 97.8% (95% CI: 88.4% - 99.6%) and the NPA was 95.6% (95% CI: 85.2% - 98.8%).

<table>
<thead>
<tr>
<th>Expected Results</th>
<th>Positive</th>
<th>Negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>44&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>46</td>
</tr>
<tr>
<td>Negative</td>
<td>1</td>
<td>43</td>
<td>44</td>
</tr>
<tr>
<td>Total</td>
<td>45</td>
<td>45</td>
<td>90</td>
</tr>
<tr>
<td>PPA</td>
<td>97.8% (95% CI: 88.4% - 99.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPA</td>
<td>95.6% (95% CI: 85.2% - 98.8%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> One specimen was reported as "SARS-CoV-2 Presumptive Pos" in initial testing and yielded a "SARS-CoV-2 Positive" test result upon retesting.

<sup>b</sup> The two false positive specimens were collected during the COVID-19 pandemic.

21 Analytical Performance

21.1 Analytical Sensitivity (Limit of Detection)–Live SARS-CoV-2 Virus

Studies were performed to determine the analytical limit of detection (LoD) of the Xpert Xpress SARS-CoV-2. The LoD of Xpert Xpress SARS-CoV-2 was established using one lot of reagent and limiting dilutions of live SARS-CoV-2 virus (USA_WA1/2020 strain) prepared in viral transport medium and NP swab clinical matrix. The concentration level with observed hit rates greater than or equal to 95% in the LoD determination study were 0.0050 and 0.0200 PFU/mL for the N2 target and E target, respectively (Table 4). Verification of the estimated LoD claim was performed on one reagent lot in replicates of 20 prepared in pooled NP swab clinical matrix. The LoD is the lowest concentration (reported as PFU/mL) of live SARS-CoV-2 virus samples that can be reproducibly distinguished from negative samples ≥ 95% of the time with 95% confidence. The claimed LoD is 0.0200 PFU/mL (Table 4).
### Table 4. LoD Determination Using USA WA1/2020 Strain

<table>
<thead>
<tr>
<th>Strain</th>
<th>Concentration (PFU/mL)</th>
<th>Total Valid Results</th>
<th>Hit Rate (%)</th>
<th>Hit Rate (%)</th>
<th>Mean Ct</th>
<th>Mean Ct</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>N2 Target</td>
<td>E Target</td>
<td>N2 Target</td>
<td>E Target</td>
</tr>
<tr>
<td>SARS-CoV-2 virus (USA_WA1/2020)</td>
<td>0.0200</td>
<td>20</td>
<td>100</td>
<td>95.0</td>
<td>38.3</td>
<td>36.4</td>
</tr>
<tr>
<td></td>
<td>0.0050</td>
<td>22</td>
<td>95.5</td>
<td>68.2</td>
<td>40.5</td>
<td>39.1</td>
</tr>
<tr>
<td></td>
<td>0.0025</td>
<td>22</td>
<td>90.9</td>
<td>36.4</td>
<td>41.5</td>
<td>39.6</td>
</tr>
<tr>
<td></td>
<td>0.0010</td>
<td>22</td>
<td>50.0</td>
<td>18.2</td>
<td>42.0</td>
<td>42.0</td>
</tr>
<tr>
<td></td>
<td>0.0005</td>
<td>22</td>
<td>45.5</td>
<td>18.2</td>
<td>41.7</td>
<td>41.5</td>
</tr>
<tr>
<td></td>
<td>0.0003</td>
<td>22</td>
<td>18.2</td>
<td>4.5</td>
<td>42.1</td>
<td>44.9</td>
</tr>
<tr>
<td></td>
<td>0.0001</td>
<td>22</td>
<td>9.1</td>
<td>0</td>
<td>42.9</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### 21.2 Analytical Reactivity (Inclusivity)

The inclusivity of Xpert Xpress SARS-CoV-2 was evaluated using *in silico* analysis of the assay primers and probes in relation to 110,206 SARS-CoV-2 sequences available (as of October 21, 2020) in the GISAID gene database for two targets, E and N2.

For the E target, 214 matching sequences were excluded due to ambiguity codes, which reduced the total to 109,992 sequences. Xpert Xpress SARS-CoV-2 had 99.14% match to the sequences with the exception of 926 sequences that had a single mismatch and 21 sequences with additional mismatches. The 21 sequences with additional mismatches were:

- One sequence contained one mismatch in the forward primer region and a second mismatch between oligos;
- One sequence contained one mismatch in the probe binding region and a second mismatch between oligos;
- One sequence contained two mismatches in the probe binding region;
- One sequence contained a 3-nucleotide deletion and multiple mismatches at the 3’-end of the probe region;
- Two sequences contained two mismatches in the forward primer region;
- Three sequences contained a 6-nucleotide deletion in the probe binding region with multiple mismatches at the 3’ end of the amplicon; and
- Twelve sequences contained a ‘AA’ dinucleotide but this lies between the oligonucleotides used in the assay.

None of these mismatches are predicted to have a negative impact on the performance of the assay.

For the N2 target, 211 matching sequences were excluded due to ambiguity codes, which reduced the total to 109,995 sequences. Xpert Xpress SARS-CoV-2 had 97.29% match to the sequences with the exception of 2,919 sequences that had a single mismatch and sixty-three sequences with two or more mismatches. The 63 sequences with additional mismatches were:

- One sequence contained two mismatches in the probe binding region and a third mismatch between oligos;
- Two sequences contained one mismatch in the forward primer region and a second mismatch in the reverse primer region;
- Six sequences contained one mismatch in the forward primer region and a second mismatch between oligos;
- Twenty-seven sequences contained one mismatch in the probe binding region and a second mismatch in the reverse primer region; and
- Twenty-seven sequences contained one mismatch in the forward primer region and a second mismatch in the probe binding region.

None of these mismatches are predicted to have a negative impact on the performance of the assay.
21.3 Analytical Specificity (Exclusivity)

An in silico analysis for possible cross-reactions with all the organisms listed in Table 5 was conducted by mapping primers and probes in the Xpert Xpress SARS-CoV-2 test individually to the sequences downloaded from the GISAID database (as of March 13, 2020). E primers and probes are not specific for SARS-CoV-2 and will detect Human and Bat SARS-coronavirus. No potential unintended cross reactivity with other organisms listed in Table 5 is expected based on the in silico analysis.

Table 5. Xpert Xpress SARS-CoV-2 Analytical Specificity Microorganisms

<table>
<thead>
<tr>
<th>Microorganisms from the Same Genetic Family</th>
<th>High Priority Organisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human coronavirus 229E</td>
<td>Adenovirus (e.g. C1 Ad. 71)</td>
</tr>
<tr>
<td>Human coronavirus OC43</td>
<td>Human Metapneumovirus (hMPV)</td>
</tr>
<tr>
<td>Human coronavirus HKU1</td>
<td>Parainfluenza virus 1-4</td>
</tr>
<tr>
<td>Human coronavirus NL63</td>
<td>Influenza A</td>
</tr>
<tr>
<td>SARS-coronavirus</td>
<td>Influenza B</td>
</tr>
<tr>
<td>MERS-coronavirus</td>
<td>Influenza C</td>
</tr>
<tr>
<td>Bat coronavirus</td>
<td>Enterovirus (e.g. EV68)</td>
</tr>
<tr>
<td></td>
<td>Respiratory syncytial virus</td>
</tr>
<tr>
<td></td>
<td>Rhinovirus</td>
</tr>
<tr>
<td></td>
<td>Chlamydia pneumoniae</td>
</tr>
<tr>
<td></td>
<td>Haemophilus influenzae</td>
</tr>
<tr>
<td></td>
<td>Legionella pneumophila</td>
</tr>
<tr>
<td></td>
<td>Mycobacterium tuberculosis</td>
</tr>
<tr>
<td></td>
<td>Streptococcus pneumoniae</td>
</tr>
<tr>
<td></td>
<td>Streptococcus pyogenes</td>
</tr>
<tr>
<td></td>
<td>Bordetella pertussis</td>
</tr>
<tr>
<td></td>
<td>Mycoplasma pneumoniae</td>
</tr>
<tr>
<td></td>
<td>Pneumocystis jirovecii (PJP)</td>
</tr>
<tr>
<td></td>
<td>Parechovirus</td>
</tr>
<tr>
<td></td>
<td>Candida albicans</td>
</tr>
<tr>
<td></td>
<td>Corynebacterium diphtheriae</td>
</tr>
<tr>
<td></td>
<td>Legionella non-pneumophila</td>
</tr>
<tr>
<td></td>
<td>Bacillus anthracis (Anthrax)</td>
</tr>
<tr>
<td></td>
<td>Moraxella catarrhalis</td>
</tr>
<tr>
<td></td>
<td>Neisseria elongate and meningitidis</td>
</tr>
<tr>
<td></td>
<td>Pseudomonas aeruginosa</td>
</tr>
<tr>
<td></td>
<td>Staphylococcus epidermidis</td>
</tr>
<tr>
<td></td>
<td>Staphylococcus salivarius</td>
</tr>
<tr>
<td></td>
<td>Leptospira</td>
</tr>
<tr>
<td></td>
<td>Chlamydia psittaci</td>
</tr>
<tr>
<td></td>
<td>Coxiella burnetii (Q-Fever)</td>
</tr>
</tbody>
</table>
Microorganisms from the Same Genetic Family | High Priority Organisms
--- | ---
 | Staphylococcus aureus

22 FDA SARS-CoV-2 Reference Panel Testing

The evaluation of sensitivity and MERS-CoV cross-reactivity was performed using reference material (T1), blinded samples and a standard protocol provided by the FDA. The study included a range finding study and a confirmatory study for LoD. Blinded sample testing was used to establish specificity and to confirm the LoD. The samples were tested using the GeneXpert Dx System. The results are summarized in Table

Table 6. Summary of LoD Confirmation Result Using the FDA SARS-CoV-2 Reference Panel

<table>
<thead>
<tr>
<th>Reference Materials Provided by FDA</th>
<th>Specimen Type</th>
<th>Product LoD (NDU/mL)</th>
<th>Cross-Reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2</td>
<td>NP Swab</td>
<td>$5.4 \times 10^3$</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>MERS-CoV</td>
<td>NP Swab</td>
<td>Not Applicable</td>
<td>Not Done</td>
</tr>
</tbody>
</table>

NDU/mL = RNA NAAT detectable units/mL

23 References


24 Cepheid Headquarters Locations

Corporate Headquarters

Cepheid
904 Caribbean Drive
Sunnyvale, CA 94089
USA
Telephone: + 1 408 541 4191
Fax: + 1 408 541 4192
www.cepheid.com

European Headquarters

Cepheid Europe SAS
Vira Solelh
81470 Maurens-Scopont
France
### 25 Table of Symbols

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>REF</td>
<td>Catalog number</td>
</tr>
<tr>
<td>IVD</td>
<td><em>In vitro</em> diagnostic medical device</td>
</tr>
<tr>
<td>2</td>
<td>Do not reuse</td>
</tr>
<tr>
<td>LOT</td>
<td>Batch code</td>
</tr>
<tr>
<td>✋</td>
<td>Consult instructions for use</td>
</tr>
<tr>
<td>⚠️</td>
<td>Caution</td>
</tr>
<tr>
<td>🏭</td>
<td>Manufacturer</td>
</tr>
<tr>
<td>🌡</td>
<td>Country of manufacture</td>
</tr>
<tr>
<td>⬇️</td>
<td>Contains sufficient for <em>n</em> tests</td>
</tr>
<tr>
<td>CONTROL</td>
<td>Control</td>
</tr>
<tr>
<td>🕒</td>
<td>Expiration date</td>
</tr>
<tr>
<td>℃</td>
<td>Temperature limitation</td>
</tr>
<tr>
<td>🚫</td>
<td>Biological risks</td>
</tr>
<tr>
<td>RXonly</td>
<td>For prescription use only</td>
</tr>
</tbody>
</table>

Cepheid
904 Caribbean Drive
Sunnyvale, CA 94089
USA
+ 1 408 541 4191
+ 1 408 541 4192

For use under Emergency Use Authorization (EUA) Only
# 26 Revision History

**Description of Changes:** 302-3562, Rev. F to Rev. G

<table>
<thead>
<tr>
<th>Section</th>
<th>Description of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cover</td>
<td>Updated per technical publications standards.</td>
</tr>
<tr>
<td>Trademark, Patents and Copyright Statements</td>
<td>Updated per legal requirements.</td>
</tr>
<tr>
<td>Throughout</td>
<td>Removed icons from left margin per Regulatory Affairs.</td>
</tr>
<tr>
<td>6</td>
<td>Simplified heading. Added &quot;GeneXpert&quot; to software name.</td>
</tr>
<tr>
<td>13.1</td>
<td>Updated figures per technical publications standards.</td>
</tr>
<tr>
<td>14</td>
<td>Updated per technical publications standards.</td>
</tr>
<tr>
<td>18</td>
<td>Added bullet point about the evaluation of a limited number of clinical specimens.</td>
</tr>
<tr>
<td>19</td>
<td>Corrected URL. Added &quot;Point of Care Settings&quot;.</td>
</tr>
<tr>
<td>24</td>
<td>Updated per technical publications standards.</td>
</tr>
<tr>
<td>26</td>
<td>Added per technical publications standards.</td>
</tr>
</tbody>
</table>